| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H30NO5P |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Benproperine phosphate is an orally active, potent actin-related protein 2/3 complex subunit 2 (ARPC2) inhibitor that reduces the rate of actin polymerization nucleation by impairing Arp2/3 function. It has potential as a cough suppressant and suppresses cancer cell migration and tumor metastasis[1]. It is supplied as a white to off-white solid (C21H30NO5P, MW 407.44) at 99.93% purity.
Physical & Chemical Properties
| CAS Number | 19428-14-9 |
|---|---|
| Molecular Formula | C21H30NO5P |
| Molecular Weight | 407.44 g/mol |
| Purity | 99.93% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | CC(N1CCCCC1)COC2=CC=CC=C2CC3=CC=CC=C3.O=P(O)(O)O |
| Signaling Pathway | Cytoskeleton |
| Solubility | In Vitro: DMSO: 100 mg/mL (245.43 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: ≥ 100 mg/mL (245.43 mM) * "≥" means soluble, but saturation unknown. |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (245.43 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | ≥ 100 mg/mL (245.43 mM) | — |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (5.11 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.08 mg/mL (5.11 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.08 mg/mL (5.11 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 900 μL corn oil. |
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 4
| Composition | saline |
|---|---|
| Result | ≥ 100 mg/mL (245.43 mM); clear solution |
Data provided by the manufacturer.
In Vitro
Benproperine phosphate (20-120 μM; 24 hours) inhibits cell viability dose-dependently[1]. Benproperine phosphate (10 μM; 24 hours) significantly inhibits migration of various types of cancer cells, and inhibits migration and invasion of DLD-1 and AsPC-1 cells with IC50 values of 1-2 μM. In MCF-10A cells, Benproperine phosphate (10 μM; 24 hours) does not affect cortactin-rich lamellipodium[1].
Cell Viability Assay[1]
| Cell Line | DLD-1, AsPC-1, CFPAC-1, A375P, A375P, MDA-MB-231, DU145, DU145 cancer cells |
|---|---|
| Concentration | 20, 40, 60, 80, 100, 120 μM |
| Incubation Time | For 24 hours |
| Result | Inhibited cell viability in a dose-dependent manner. |
In Vivo
Primary pancreatic tumor growth is inhibited by Benproperine phosphate (50, 100 mg/kg; oral gavage; 5 days weekly for 4 weeks)[1]. In mice, Benproperine phosphate markedly decreases lung metastasis of AsPC-1 cells (56.1% inhibition). Benproperine phosphate significantly suppresses liver metastasis of HCT-116 cells by 78.9% and of DLD-1 cells by 78.2%[1].
| Animal Model | Female BALB/c nude mice of 6-week-old with AsPC-1 cells[1] |
|---|---|
| Dosage | 50, 100 mg/kg |
| Administration | Oral gavage; 5 days per week for 4 weeks |
| Result | Inhibited primary pancreatic tumor growth compared to the vehicle control (47.7% inhibition) without body weights change. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. Adv Sci (Weinh) 2026 Mar;13(16):e13310. PMID: 41589654
DDX3X Promotes Rotavirus Infection and Serves as an Antiviral Target. Transbound Emerg Dis 2025 Nov 21:2025:5822897. PMID: 41323147
